Nutrition additive supply chains 'nervous' as Suez blockage continues
Some seaborne deliveries are being rerouted or switched to air transportation as efforts to re-float stricken Ever Given container vessel move into fourth day
The logjam in the Suez canal caused by a stricken container ship wedged across the vital trade route has caused nervousness to human and animal nutrition additive supply chains, with some deliveries being switched to air transportation or put on hold, according to online trade platform and data provider, Kemiex.
Earlier this week, the 200,000-ton Panama-registered Ever Given, operated by shipping company Evergreen and bound for Rotterdam in the Netherlands from China became stuck in the Egyptian canal.
Efforts to re-float the vessel and free up the waterway are ongoing.
Stefan Schmidinger, partner at Kemiex told CPHI Online that three days after the incident, it remains unclear how long the waterway will be affected, with the best case scenario being a resolution next week, “but if cargo needs to be unloaded first this would multiply to three to six weeks in a base case.”
According to ship tracking platforms, an increasing number of vessels have changed course to take the route around Africa, causing a one-week delay to arrive at their destination, and a two-week delay for a full Asia-Europe round trip.
Schmidinger said this course of action results in a 10-20% reduction of carrier and container capacity on this lane, as well as additional fuel consumption and emissions, in a freight market that has been operating at its limits amid record rates for the last year.
“Human and animal nutrition additives, as well as other bulk chemicals, are being impacted directly, causing significant nervousness among supply chain managers,” he said. “A few new factory deliveries have reportedly been re-booked to air as the additional cost was secondary to a timely delivery, but more shippers have rushed to secure space or even put April deliveries on-hold.”
Schmidinger said the bottleneck could prove to be a boost to ‘niche’ freight trains connecting China-Europe typically costing less than air but moving cargo faster than sea.
Container freight rates have spiralled over the last few months amid a shortage of containers in Asia as Chinese exports recovered from the effects of the coronavirus pandemic. The Freightos FBX11 China-North Europe route index was marked at $7,500/FEU on March 25, up from around $2,500/FEU in November.
Schmidinger confirmed that as pharmaceutical ingredients are mostly airborne, the Suez incident has yet to cause any supply disruption for the sector.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.